Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-infected Children in Uganda

被引:0
作者
Winnie Bikaako-Kajura
Emmanuel Luyirika
David W. Purcell
Julia Downing
Frank Kaharuza
Jonathan Mermin
Samuel Malamba
Rebecca Bunnell
机构
[1] CDC-Uganda,Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention
[2] Global AIDS Program,Centers for Disease Control and Prevention, Uganda
[3] The Mildmay Centre,undefined
[4] Uganda,undefined
[5] Centers for Disease Control and Prevention,undefined
[6] C/O Uganda Virus Research Institute,undefined
来源
AIDS and Behavior | 2006年 / 10卷
关键词
Pediatrics; AIDS; Adherence; Antiretrovirals; Cotrimoxazole;
D O I
暂无
中图分类号
学科分类号
摘要
Pediatric adherence to daily drug regimens has not been widely assessed in Africa where majority of HIV infected children live. Using in-depth interviews of 42 HIV-infected children taking ART and/or cotrimoxazole prophylaxis, and 42 primary caregivers, at a comprehensive HIV/AIDS clinic in Uganda, we evaluated their adherence experiences for purposes of program improvement. Daily drug regimens provided by the pediatric clinic included cotrimoxazole prophylaxis as well as ART and cotrimoxazole combined. Complete disclosure of HIV status by caregivers to children and strong parental relationships were related to good adherence. Structural factors including poverty and stigma were barriers to adherence even for children who had had complete disclosure and a supportive relationship with a parent. To ensure adherence to life-extending medications, our findings underscore the need for providers to support caregivers to disclose, provide on-going support and maintain open communication with HIV-infected children taking cotrimoxazole prophylaxis and ART.
引用
收藏
页码:85 / 93
页数:8
相关论文
共 113 条
[1]  
Belzer M. E.(1999)Antiretroviral adherence issues among HIV-positive adolescents and young adults Journal of Adolescent Health 25 316-319
[2]  
Fuchs D. N.(2004)Disclosure model for pediatric patients living with HIV in Puerto Rico: Design, implementation, and evaluation Journal of Developmental and Behavioral Pediatrics 25 181-189
[3]  
Luftman G. S.(2000)Compliance to combination antiretroviral therapy in HIV-1 infected children International Journal of Antimicrobial Agents 16 371-372
[4]  
Tucker D. J.(2004)Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial Lancet 364 1865-1871
[5]  
Blasini I.(2005)Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d’Ivoire Journal of Acquired Immune Deficiency Syndromes 40 498-500
[6]  
Chantry C.(2004)Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire AIDS 18 1905-1913
[7]  
Cruz C.(2002)Diagnostic disclosure to HIV-infected children: How parents decide when and what to tell Clinical Child Psychology and Psychiatry 7 85-99
[8]  
Ortiz L.(2000)Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic Journal of the National Medical Association 92 55-61
[9]  
Salabarria I.(1997)Potential factors affecting adherence with HIV therapy [editorial] AIDS 11 1665-1670
[10]  
Scalley N.(2004)Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and HIV viral load among persons with HIV in rural Uganda Lancet 364 1428-1434